NCT00388089

Who might be able to join this trial:

• You have been diagnosed with an advanced solid tumor (a cancer that has spread or cannot be removed), confirmed by a lab test on a tissue or cell sample
• Your cancer has continued to grow or spread after at least one standard treatment, OR there is no standard curative treatment available for your condition, OR you are not well enough to receive standard treatment
• If you have small cell lung cancer, you may be considered after a certain stage of the trial is reached, and you must have a tumor that can be safely biopsied
• Your cancer can be measured or detected using scans or other methods (for example, fluid build-up around the lungs, fluid in the abdomen, or bone spread)
• If you have cancer that spread to the brain but it has been treated with surgery or radiation and is no longer causing symptoms, you may still be eligible — as long as you have been off steroids and anti-seizure medications for at least 4 weeks and your condition is neurologically stable
• You are well enough to carry out most daily activities (a functional ability score of 60–100% on a standard medical scale)
• Your life expectancy is at least 3 months
• Your blood counts and organ function meet the required levels, including healthy enough white blood cells, platelets, kidney function, and liver function (confirm with trial site)
• You are not pregnant or breastfeeding, and if you could become pregnant, you have had a negative pregnancy test
• If you are able to have children, you are willing to use effective birth control during the trial

Who may not be able to join:

• You have significant nerve damage or nerve-related symptoms that developed in the past 14 days (confirm with trial site)
• You have a known allergy or sensitivity to bortezomib, boron, or mannitol
• You have had a heart attack in the past 6 months
• You have moderate to severe heart failure (classified as Class III or IV by a standard medical scale)
• You have uncontrolled chest pain, serious irregular heart rhythms, or signs of reduced blood flow to the heart shown on a heart tracing (ECG)
• You have previously been treated with topotecan hydrochloride or bevacizumab
• You have received any experimental drug treatment within the past 14 days
• You are currently taking certain anti-seizure medications that are broken down by a specific liver pathway (called the cytochrome P450 pathway) — confirm which medications this applies to with the trial site
• You received chemotherapy less than 4 weeks ago and have not yet recovered from its effects
• You received radiation therapy less than 2 weeks ago and have not yet recovered from its effects

Important: Always verify eligibility with the trial site directly before applying.